Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
Dapagliflozin Effective in T2D with HFrEF Regardless of Type of Background T2D Therapy
VIDEO: Kieran Docherty, MBChB, discusses results of the DAPA-HF analysis on the impact of background T2D therapy on clinical outcomes in patients with T2D and HFrEF.
In the DAPA-HF trial, the SGLT-2 inhibitor dapagliflozin improved clinical outcomes in patients wtih heart failure with reduced ejection fraction, with or without type 2 diabetes (T2D). Kieran Docherty, MBChB, discusses results of an important DAPA-HF subanalysis that found dapagliflozin benefits are not affected by background T2D therapy or the type of therapy. Results were presented at the recent 2020 American Diabetes Association Scientific Sessions.
Recent Videos
Related Content
